Literature DB >> 11122876

Radiotherapy for brain tumors.

M P Mehta1, W A Tomé, G H Olivera.   

Abstract

Over the last 2 years, several advances have been made in the field of radiotherapy for brain tumors. Key advances are summarized in this review. Crucial technologic advances, such as radiosurgery, fractionated stereotactic radiotherapy, and intensity-modulated radiotherapy, are discussed. Better understanding of the interaction between the processes of angiogenesis, apoptosis, cell-cycle regulation, and signal transduction and the effects of ionizing radiation has made it clear that many of these "new agents" are, in fact, valuable modulators of the radiation response. Another exciting molecular discovery is the recognition of radiation-induced promoters that can be exploited to cause spatially and temporally configured expression of selected genes; this approach may represent the ideal application of conformal radiation techniques in the future, yielding well-defined genetic changes in specifically targeted tissues. The final "frontier" covered in this review is the newer categories of radiosensitizers, ranging from topoisomerase-I inhibitors, to expanded metalloporphyrins, to oxygen- dissociating agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122876     DOI: 10.1007/s11912-000-0064-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  21 in total

1.  Tomotherapy.

Authors:  T R Mackie; J Balog; K Ruchala; D Shepard; S Aldridge; E Fitchard; P Reckwerdt; G Olivera; T McNutt; M Mehta
Journal:  Semin Radiat Oncol       Date:  1999-01       Impact factor: 5.934

2.  p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors.

Authors:  D A Haas-Kogan; S S Kogan; G Yount; J Hsu; M Haas; D F Deen; M A Israel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-15       Impact factor: 7.038

3.  Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.

Authors:  S W Young; F Qing; A Harriman; J L Sessler; W C Dow; T D Mody; G W Hemmi; Y Hao; R A Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin.

Authors:  D H Gorski; H J Mauceri; R M Salloum; S Gately; S Hellman; M A Beckett; V P Sukhatme; G A Soff; D W Kufe; R R Weichselbaum
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

5.  Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enhances radiation toxicity.

Authors:  L Geng; S Walter; E Melian; A T Vaughan
Journal:  Radiat Res       Date:  1998-07       Impact factor: 2.841

6.  Combined radiation and p53 gene therapy of malignant glioma cells.

Authors:  B Badie; C S Goh; J Klaver; H Herweijer; D A Boothman
Journal:  Cancer Gene Ther       Date:  1999 Mar-Apr       Impact factor: 5.987

7.  The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.

Authors:  J P Lamond; M P Mehta; D A Boothman
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

8.  Expression of an altered epidermal growth factor receptor by human glioblastoma cells.

Authors:  P A Steck; P Lee; M C Hung; W K Yung
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

9.  Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo.

Authors:  B A Teicher; J S Wong; H Takeuchi; L M Gravelin; G Ara; D Buxton
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

Review 10.  A tiger behind many doors: multiple genetic pathways to malignant glioma.

Authors:  D N Louis; J F Gusella
Journal:  Trends Genet       Date:  1995-10       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.